Вы и ваши гормоны. Наука о женском здоровье и гормональной контрацепции

208. Svendal, G., Berk, M., Pasco, J. A. et al. (2012). The use of hormonal contraceptive agents and mood disorders in women. Journal of Affective Disorders, 140(1), 92–96. doi:10.1016/­j.jad.­2012.­03.­030; Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162. doi:10.1001/­jama­psychiatry.­2016.­2387; Toffol, E., Heikinheimo, O., Koponen, P. et al. (2011). Hormonal contraception and mental health: Results of a population-based study. Human Reproduction, 26(11), 3085–3093. doi:10.1093/­humrep/­der­269.

209. Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162. doi:10.1001/­jama­psychiatry.­2016.­2387.

210. Bäckström, T., Hansson-Malmström, Y., Lindhe, B. et al. (1992). Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations. Contraception, 46(3), 253–268. doi:10.1016/­0010-7824­(92)­90006-f; Bancroft, J., Sanders, D., Warner, P., & Loudon, N. (1987). The effects of oral contraceptives on mood and sexuality: A comparison of triphasic and combined preparations. Journal of Psychosomatic Obstetrics and Gynecology, 7(1), 1–8. doi:10.3109/­01­674­828­709­019­585.

211. Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162. doi:10.1001/­jama­psychiatry.­2016.­2387.

212. Ernst, U., Baumgartner, L., Bauer, U., & Janssen, G. (2002). Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: Results of an observational clinical evaluation. European Journal of Contraception and Reproductive Health Care, 7(4), 238–243. doi:10.1080/ejc.7.4.238.243.

213. Poromaa, I. S., & Segebladh, B. (2012). Adverse mood symptoms with oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica, 91(4), 420–427. doi:10.1111/j.­1600-0412.­2011.­01333.x; Freeman, E. W., Kroll, R., Rapkin, A.et al. (2001). Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women’s Health and Gender-Based Medicine, 10(6), 561–569. doi:10.1089/­152­460­901­525­431­48; Parsey, K. S., & Pong, A. (2000). An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception, 61(2), 105–111. doi:10.1016/s0010-7824(00)00083-4; Sillem, M., Schneidereit, R., Heithecker, R., & Mueck, A. O. (2009). Use of an oral contraceptive containing drospirenone in an extended regi­men. European Journal of Contraception and Reproductive Health Care, 8(3), 162–169. doi:10.1080/­ejc.­8.3.­162.­169; Apter, D., Borsos, A., Baumgärtner, W. et al. (2003). Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. European Journal of Contraception and Reproductive Health Care, 8(1), 37–51. doi:10.1080/­713­604­397.

214. Deijen, J., Duyn, K., Jansen, W., & Klitsie, J. (1992). Use of a monophasic, low-dose oral contraceptive in relation to mental functioning. Contraception, 46(4), 359–367. doi:10.1016/­0010-7824­(92)­90098-e.

215. Schultz-Zehden, B., & Boschitsch, E. (2006). User experience with an oral contraceptive containing ethinylestradiol 30μg30 and drospirenone 3mg (Yasmin®) in clinical practice. Treatments in Endocrinology, 5(4), 251–256. doi:10.2165/­000­246­77-200­605­040-00006; Short, M. (2009). User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 μg (Yasminelle®) in clinical practice. Clinical Drug Investigation, 29(3), 153–159. doi:10.2165/­000­440­11-2009­29­030-00002.